Reference number
1753-H

SPECIALTY QUANTITY LIMIT PROGRAM

GILOTRIF (afatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Gilotrif 20 mg tablets	30 per 30 days	• Initial dose: 40 mg once daily • Dose adjustment for severe renal impairment: 30 mg once daily • Dose adjustment for adverse reactions: resume treatment when the adverse reaction fully resolves, returns to baseline, or improves to Grade 1. Reinstitute at a reduced dose (10 mg per day less than the dose at which the adverse reaction occurred) • Dose adjustment for drug interactions: ○ P-gp inhibitors: reduce daily dose by 10 mg. Resume the previous dose after discontinuation of the P-gp inhibitor. ○ P-gp inducers: increase daily dose by 10 mg. Resume the previous dose after discontinuation of the P-gp inducer.
Gilotrif 30 mg tablets	30 per 30 days	
Gilotrif 40 mg tablets	30 per 30 days	

III. REFERENCE

1. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2018.

CVS caremark™